Cartalax
guinea pig
The Dose Guy’s verdictAug 29, 20262 sources
Cartalax is a Khavinson bioregulator, a Russian ultra-short peptide claimed to normalize connective tissue and cartilage. The evidence behind it is cell studies from a single lab, a narrative review with unverifiable clinical claims, and nothing else. No randomized trial, no quantified outcome, no published safety data, no pharmacokinetics. If you are looking for joint and connective-tissue support with actual receipts, this is not where you start.
What it is
Cartalax is a tripeptide, three amino acids, Ala-Glu-Asp, from the Khavinson school of bioregulators. The theory behind these ultra-short peptides is that they reach the nucleus and regulate gene expression for specific tissue types. Cartalax is the connective-tissue entry, claimed to normalize chondrocyte function and cartilage matrix synthesis.
In cell experiments, it activated the expected markers: SOX9, aggrecan, type II collagen, the proteins you would want a cartilage-repair molecule to turn on. It also dialed down senescence markers in aging chondrocytes. Those are legitimate observations in a dish, from a single Russian lab with no Western replication. What they are not is evidence that swallowing or injecting a tripeptide produces any of those effects in a human joint. If connective-tissue healing is the goal, BPC-157 and TB-500 have far deeper community track records and broader preclinical backing.
What the research shows
The published evidence is three papers from one research group, all cell-based, plus a narrative review:
Realistic protocols
I am not building a dosing protocol out of cell studies and a vague review claim. The bioregulator community runs cartalax orally as capsules, typically around 10 to 20 mg per day in courses of 10 to 30 days with breaks between them. That is community convention, not studied dosing, and no human PK data exists to tell you what reaches your joints after you swallow it. If you arrived here from a peptide vendor selling a lyophilized vial, know that the injectable route has no tested regimen behind it at all, not even the thin community convention the capsules have. If you run it in any form, keep the course short, keep a log, and understand you are generating your own n=1 data where nobody else has published theirs.
Side effects
No side effect has ever been measured in a human study, because no human study has been published:
